fda tirzepatide shortage march 19th Announced Removal of from the Drug List FDA confirms tirzepatide shortage is – FDA Says Shortage for GLP-1

Many commercial plans explicitly exclude weight management medications from their formulary

More recent evidence indicates that sustained GIP receptor agonism in the presence of GLP-1 activation enhances insulin sensitivity and may preferentially reduce visceral adipose tissue

All currently approved injectable GLP-1RAs have demonstrated CV safety (non-inferiority) in CVOTs [12, 19,20,21,22,23], but only four have demonstrated both CV safety and superiority relative to standard of care [12, 20, 22, 23]

This early worsening manifests as: Increased vitreous hemorrhage (bleeding into the eye) New or worsening macular edema (retinal swelling) Progression of proliferative changes Increased floaters from vitreous shifts Importantly, this appears to be a change early on (about three to six months) while taking the medication and should eventually improve the retinopathy and edema

Make sure you choose a licensed and reputable pharmacy